The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions

Published:2013-01-30 Issue:11 Volume:53 Page:2609-2618
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Kacker Seema¹²³⁴,Ness Paul M.¹²³⁴,Savage William J.¹²³⁴,Frick Kevin D.¹²³⁴,McCullough Jeffrey¹²³⁴,King Karen E.¹²³⁴,Tobian Aaron A.R.¹²³⁴

Affiliation:

1. Department of Health Policy and Management; Bloomberg School of Public Health; Johns Hopkins University; Baltimore Maryland

2. Department of Pathology; Johns Hopkins University; Baltimore Maryland

3. Department of Pathology; Brigham and Women's Hospital; Boston Massachusetts

4. Department of Laboratory Medicine and Pathology; University of Minnesota; Minneapolis Minnesota

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.12095/fullpdf

Reference27 articles.

1. Allergic transfusion reactions: an evaluation of 273 consecutive reactions;Domen;Arch Pathol Lab Med,2003

2. Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial;Enright;Transfusion,2003

3. Using lean techniques to define the platelet (PLT) transfusion process and cost-effectiveness to evaluate PLT dose transfusion strategies;Riley;Transfusion,2012

4. Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children;Sanders;Br J Haematol,2005

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review;PharmacoEconomics - Open;2023-06-26

2. Atezolizumab plus bevacizumab versus nivolumab as first‐line treatment for advanced or unresectable hepatocellular carcinoma: A cost‐effectiveness analysis;Cancer;2022-09-16

3. Adverse transfusion reactions and what we can do;Expert Review of Hematology;2022-08-03

4. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis;Frontiers in Pharmacology;2022-07-19

5. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma;JAMA Network Open;2021-04-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3